STAAR Surgical authorizes USD 50 million share repurchase program

By Public Technologies
  • STAAR Surgical’s board, at a regularly scheduled meeting, authorized a share repurchase program of up to USD 50 million.
  • Buybacks may be executed in the open market, via private transactions, structured agreements, block trades, or Rule 10b5-1 plans.
  • Repurchase timing, price, and volume will be set at management’s discretion; the program can be modified, suspended, or ended.
  • Program is expected to run for 12 months; funding planned from free cash flow and cash on hand.
  • As of July 3, 2026, STAAR reported USD 181.5 million in cash and investments, no debt; about 50,100,000 shares outstanding as of Aug. 7, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202609241601BIZWIRE_USPR_____20260924_BW354417) on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.